➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Mallinckrodt
Moodys
AstraZeneca

Last Updated: June 4, 2020

DrugPatentWatch Database Preview

SAVELLA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Savella patents expire, and what generic alternatives are available?

Savella is a drug marketed by Allergan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in twenty-seven countries.

The generic ingredient in SAVELLA is milnacipran hydrochloride. There are twenty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Savella

Savella was eligible for patent challenges on January 14, 2013.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (milnacipran hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for SAVELLA
Drug Prices for SAVELLA

See drug prices for SAVELLA

Drug Sales Revenue Trends for SAVELLA

See drug sales revenues for SAVELLA

Recent Clinical Trials for SAVELLA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 4
University of OttawaPhase 4
Spencer Dorn, MD, MPHPhase 2

See all SAVELLA clinical trials

Recent Litigation for SAVELLA

Identify potential future generic entrants

District Court Litigation
Case NameDate
FOREST LABORATORIES HOLDINGS, LTD. v. STRIDES PHARMA GLOBAL PTE LIMITED2017-10-06
Forest Laboratories Holdings, Ltd. v. Strides Pharma Global PTE Limited2017-10-05
Forest Laboratories Holdings Ltd. v. Apotex Corp.2013-09-23

See all SAVELLA litigation

Synonyms for SAVELLA
(+-)-cis-2-Aminomethyl-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R-cis)-Milnacipran Hydrochloride
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride; F 2207; Midalcipran; Toledomin
(1RS,2SR)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1S-cis)-Milnacipran HCl
(1S-cis)-Milnacipran Hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride
(Z)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
1-Phenyl-1-(diethylaminocarbonyl)-2-(aminomethyl)cyclopropane hydrochloride
101152-94-7
152M947
175131-60-9
175131-61-0
371U2ZK31U
A14391
AB0108218
AB1004578
AKOS015950801
AKOS025311514
AOB6178
API0003393
AS-12868
AT-28508
BCP05817
CAS-101152-94-7
CCG-101034
CCG-231710
CHEBI:31854
CHEMBL1237129
CHEMBL2105732
cis-(+-)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
CPD000449266
CS-2010
CS-4972
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (Z)-, monohydrochloride
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, hydrochloride (1:1), (1S,2R)-
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, monohydrochloride, (1R,2S)-rel-
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, monohydrochloride, cis-(+-)-
D01107
D10133
Dalcipran
DSSTox_CID_26785
DSSTox_GSID_46785
DSSTox_RID_81903
DTXSID4046785
F 2207
F 2695 hydrochloride
F-2207
F-2695 HYDROCHLORIDE
F2207
F2695 HYDROCHLORIDE
Fetzima
Fetzima (TN)
HY-B0168A
HY-B0168B
Ixel
J-011063
J10386
Joncia
K-0218
KS-1274
Levomilnacipran HCl
LEVOMILNACIPRAN HYDROCHLORIDE
Levomilnacipran hydrochloride (USAN)
Levomilnacipran hydrochloride [USAN]
LS-58540
LS-58541
M2133
MFCD00901293
Midalcipran hydrochloride
Milnacipran ((1S-cis) hydrochloride)
Milnacipran (hydrochloride)
Milnacipran HCl
Milnacipran hydrochloride
Milnacipran hydrochloride (JAN/USAN)
Milnacipran hydrochloride [USAN]
Milnacipran Hydrochloride 1.0 mg/ml in Methanol (as free base)
Milnacipran hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Milnacipran hydrochloride, >=98% (HPLC), solid
milnacipran-hydrochloride
MLS000758229
MLS001424149
NC00284
NCGC00168780-01
Q27256611
Q27288221
s3140
s5693
SAM001247035
Savella (TN)
SB17448
SC-15864
SCHEMBL1148742
SCHEMBL161558
SMR000449266
SW197664-2
TN-912
Toledomin
Toledomin (TN)
Tox21_112641
UNII-371U2ZK31U
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-NQQJLSKUSA-N
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-PBCQUBLHSA-N
Z-2 Aminomethyl-1-phenyl-N,N-diethylcyclopropane-carboxamide hydrochloride
Paragraph IV (Patent) Challenges for SAVELLA
Tradename Dosage Ingredient NDA Submissiondate
SAVELLA TABLET;ORAL milnacipran hydrochloride 022256 2013-01-14

US Patents and Regulatory Information for SAVELLA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Mallinckrodt
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.